The stock of BeyondSpring Inc. (BYSI, Financial) displayed significant volatility, with its value surging by 7.27%. The stock is currently priced at $2.36 per share, featuring a trading volume of 29,629 shares and a turnover rate of 0.07%, with an amplitude of 6.00%.
Recent financial reports indicate that BeyondSpring Inc. achieved a revenue of $1,000,000 and a net loss of $7.26 million, resulting in an earnings per share (EPS) of -$0.19. The company's price-to-earnings (P/E) ratio stands at -5.65.
Within the biotechnology sector, BeyondSpring Inc. experienced a marginal sector-wide increase of 0.05%. Comparable stocks such as Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024, Nkgen Biotech Inc C/Wts 31/05/2028, and Capricor Therapeutics, Inc. saw notable growth. Active stocks in the same sector included Aditxt, Inc., Gri Bio, Inc., and Seelos Therapeutics, Inc., with turnover rates of 162.77%, 55.89%, and 55.05% respectively. Stocks with considerable amplitude in the sector were Tc Biopharm (Holdings) Plc C/Wts 10/02/2028, Capricor Therapeutics, Inc., and Kezar Life Sciences, Inc., showing amplitudes of 85.25%, 45.53%, and 39.49% respectively.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies and immuno-oncology drugs. It has two reportable segments: the Plinabulin pipeline and the TPD platform.
